Antibodies
3 May 2011
XOMA 3AB, a Novel Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase 1 Clinical Testing26 April 2011
Dyax Corp. and Five Prime Therapeutics, Inc. Enter Into Research Agreement for Discovery of Therapeutic Antibodies21 April 2011
Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)18 April 2011
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration18 April 2011
FDA Approves ACTEMRA (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)14 April 2011
Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease12 April 2011
Morphotek Receives Grant to Support Development of Therapeutic Antibodies against Biowarfare AgentsNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports